Envlomet SR (enavogliflozin/metformin) / Daewoong Pharma - LARVOL DELTA

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus (clinicaltrials.gov) - P=N/A | N=15000 | Active, not recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Trial completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia (clinicaltrials.gov) - P=N/A | N=12000 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus (clinicaltrials.gov) - P=N/A | N=15000 | Active, not recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

To Evaluate the Efficacy and Safety of Enavogliflozin in Patients With Type II Diabetes Mellitus Accompanied by Hypertension or Dyslipidemia (clinicaltrials.gov) - P=N/A | N=12000 | Not yet recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD.

New trial • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus (clinicaltrials.gov) - P=N/A | N=15000 | Recruiting | Sponsor: Daewoong Pharmaceutical Co. LTD. | Not yet recruiting ➔ Recruiting | N=10000 ➔ 15000

Enrollment change • Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus